NEW YORK – Interpace Diagnostics reported this morning that its second quarter revenues rose 14 percent year over year, primarily due to the expansion of its existing products in the gastroenterological and endocrine space. 

For the three months ended June 30, the Parsippany, New Jersey-based firm reported revenues of $6.3 million, up from $5.5 million in the year-ago quarter but missing the consensus Wall Street estimate of $6.6 million.